Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | FABP3 | P05413 | 2/20 | 0.31 |
| ▸ | FABP4 | P15090 | 2/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25547481 | 0.84 | GABRA1 (0.37) | HTTALDH1A1LMNAGABRA1GABRB2 | |
| SCHEMBL26345761 | 0.84 | GABRA1 (0.37) | HTTALDH1A1LMNAGABRA1GABRB2 | |
| Boric Acid SCHEMBL28918370 | 0.82 | GABRA1 (0.32) | ALDH1A1GABRA1GABRB2TRPA1PTGS1 | |
| SCHEMBL599485 | 0.81 | ALDH1A1 (0.42) | HTTALDH1A1LMNAGABRA1GABRB2 | |
| SCHEMBL3363012 | 0.81 | LMNA (0.40) | HTTALDH1A1LMNAGABRA1GABRB2 | |
| Hydrogen Peroxide SCHEMBL11210753 | 0.76 | FABP3 (0.44) | HTTALDH1A1LMNAGABRA1GABRB2 | |
| Hydrogen Peroxide SCHEMBL11574286 | 0.76 | FABP3 (0.44) | HTTALDH1A1LMNAGABRA1GABRB2 | |
| SCHEMBL5044874 | 0.74 | — | — | |
| SCHEMBL13871115 | 0.74 | — | — | |
| SCHEMBL21882586 | 0.73 | GABRA1 (0.31) | HTTALDH1A1GABRA1GABRB2FABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210052561-A1 | TARGETING ASPARTATE BETA-HYDROXYLASE SUPPRESSES TUMOR MALIGNANCY AND METASTASIS | MIDWESTERN UNIVERSITY | 2021-02-25 | — | — | US | disclosed |
| US-10227346-B2 | Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof | PFIZER INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180170928-A1 | Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | PFIZER INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9676780-B2 | Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2017-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227346-B2 | Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof | RORC, RORB, RORA | HTT 3718/4885ALDH1A1 1091/4885LMNA 3808/4885 |
| US-20180170928-A1 | Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | RORC, RORB, RORA | HTT 4216/4885ALDH1A1 715/4885LMNA 4059/4885 |
| US-20210052561-A1 | TARGETING ASPARTATE BETA-HYDROXYLASE SUPPRESSES TUMOR MALIGNANCY AND METASTASIS | ASPH, GOT1, FOLH1 | HTT 2852/4885ALDH1A1 35/4885LMNA 4443/4885 |
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | HTT 4049/4885ALDH1A1 649/4885LMNA 3182/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | HTT 4049/4885ALDH1A1 649/4885LMNA 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.